Header Logo

Connection

PAUL CORN to Humans

Back to Details
This is a "connection" page, showing publications PAUL CORN has written about Humans.
PAUL CORN
Connection Strength
0.424
Humans
  1. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 06 01; 9(6):825-834.
    View in: PubMed
    Score: 0.018
  2. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
    View in: PubMed
    Score: 0.014
  3. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443.
    View in: PubMed
    Score: 0.014
  4. Taxane-based Combination Therapies for Metastatic Prostate Cancer. Eur Urol Focus. 2019 05; 5(3):369-380.
    View in: PubMed
    Score: 0.012
  5. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. 2014 Sep; 33(2-3):595-606.
    View in: PubMed
    Score: 0.010
  6. Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5856-66.
    View in: PubMed
    Score: 0.009
  7. Optimal therapy sequencing in metastatic castration-resistant prostate cancer. Curr Oncol Rep. 2013 Jun; 15(3):217-23.
    View in: PubMed
    Score: 0.009
  8. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):540-5.
    View in: PubMed
    Score: 0.009
  9. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011 Nov 16; 103(22):1665-75.
    View in: PubMed
    Score: 0.008
  10. Using methylation analysis to assess tumor heterogeneity in familial breast cancer. Cancer Biol Ther. 2011 Jun 15; 11(12):1065-6.
    View in: PubMed
    Score: 0.008
  11. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines. Cancer Biol Ther. 2010 Dec 15; 10(12):1315-25.
    View in: PubMed
    Score: 0.008
  12. Methylation marks the path for biomarker development in breast cancer research. Cancer Biol Ther. 2009 Dec; 8(23):2260-2.
    View in: PubMed
    Score: 0.007
  13. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther. 2009 Feb; 8(3):245-52.
    View in: PubMed
    Score: 0.007
  14. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther. 2008 Oct; 7(10):1619-27.
    View in: PubMed
    Score: 0.007
  15. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma: defining the pancreatic cancer [corrected] epigenome. Cancer Biol Ther. 2008 Jul; 7(7):1157-9.
    View in: PubMed
    Score: 0.006
  16. Hypoxic regulation of mRNA expression. Cell Cycle. 2008 Jul 01; 7(13):1916-24.
    View in: PubMed
    Score: 0.006
  17. Hypoxic regulation of miR-210: shrinking targets expand HIF-1's influence. Cancer Biol Ther. 2008 Feb; 7(2):265-7.
    View in: PubMed
    Score: 0.006
  18. Role of the ubiquitin proteasome system in renal cell carcinoma. BMC Biochem. 2007 Nov 22; 8 Suppl 1:S4.
    View in: PubMed
    Score: 0.006
  19. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther. 2007 Dec; 6(12):1858-66.
    View in: PubMed
    Score: 0.006
  20. Reactivation of p53 function with a demethylating agent. Cancer Biol Ther. 2006 Sep; 5(9):1161-2.
    View in: PubMed
    Score: 0.006
  21. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther. 2005 Nov; 4(11):1285-94.
    View in: PubMed
    Score: 0.005
  22. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
    View in: PubMed
    Score: 0.005
  23. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression. Clin Cancer Res. 2023 11 01; 29(21):4464-4478.
    View in: PubMed
    Score: 0.005
  24. Metastases-Targeting Radiotherapy and ADT-Reply. JAMA Oncol. 2023 Nov 01; 9(11):1587-1588.
    View in: PubMed
    Score: 0.005
  25. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet. 2003 Nov; 35(3):229-37.
    View in: PubMed
    Score: 0.005
  26. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.005
  27. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3).
    View in: PubMed
    Score: 0.004
  28. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis. 2003 Jan; 24(1):47-51.
    View in: PubMed
    Score: 0.004
  29. Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. Cancer Res. 2022 09 02; 82(17):3158-3171.
    View in: PubMed
    Score: 0.004
  30. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):910-918.
    View in: PubMed
    Score: 0.004
  31. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
    View in: PubMed
    Score: 0.004
  32. Derangement of growth and differentiation control in oncogenesis. Bioessays. 2002 Jan; 24(1):83-90.
    View in: PubMed
    Score: 0.004
  33. Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer. JAMA Netw Open. 2021 12 01; 4(12):e2140803.
    View in: PubMed
    Score: 0.004
  34. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. Eur Urol Oncol. 2022 04; 5(2):164-175.
    View in: PubMed
    Score: 0.004
  35. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021 10; 9(10).
    View in: PubMed
    Score: 0.004
  36. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267.
    View in: PubMed
    Score: 0.004
  37. Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer. Mol Cancer Res. 2021 12; 19(12):2036-2045.
    View in: PubMed
    Score: 0.004
  38. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.004
  39. PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer. Mol Cancer Ther. 2021 09; 20(9):1680-1691.
    View in: PubMed
    Score: 0.004
  40. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264.
    View in: PubMed
    Score: 0.004
  41. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med. 2021 04; 10(7):2341-2349.
    View in: PubMed
    Score: 0.004
  42. Incidental Detection of Urothelial Carcinoma on 18F-Fluciclovine PET/CT. Clin Nucl Med. 2021 Feb 01; 46(2):e114-e115.
    View in: PubMed
    Score: 0.004
  43. Combination of Radiation Therapy and?Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men?With High- and Intermediate-Risk Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1271-1278.
    View in: PubMed
    Score: 0.004
  44. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.004
  45. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol. 2020 07 06; 21(1):162.
    View in: PubMed
    Score: 0.004
  46. Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer. 2020 07; 27(7):R255-R265.
    View in: PubMed
    Score: 0.004
  47. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5.
    View in: PubMed
    Score: 0.004
  48. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clin Cancer Res. 2020 08 01; 26(15):4143-4153.
    View in: PubMed
    Score: 0.004
  49. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).
    View in: PubMed
    Score: 0.004
  50. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75.
    View in: PubMed
    Score: 0.004
  51. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
    View in: PubMed
    Score: 0.004
  52. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6839-6851.
    View in: PubMed
    Score: 0.003
  53. Prostate Cancer: Quo Vadis? Eur Urol. 2019 Dec; 76(6):709-711.
    View in: PubMed
    Score: 0.003
  54. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2020 10; 3(5):687-694.
    View in: PubMed
    Score: 0.003
  55. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol. 2020 02; 3(1):119-127.
    View in: PubMed
    Score: 0.003
  56. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 04 01; 36(10):991-999.
    View in: PubMed
    Score: 0.003
  57. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2018 02 01; 24(3):696-707.
    View in: PubMed
    Score: 0.003
  58. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589.
    View in: PubMed
    Score: 0.003
  59. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017 May 23; 10(480).
    View in: PubMed
    Score: 0.003
  60. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep. 2017 02 21; 18(8):1970-1981.
    View in: PubMed
    Score: 0.003
  61. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.003
  62. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem. 2017; 24(15):1586-1606.
    View in: PubMed
    Score: 0.003
  63. Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clin Genitourin Cancer. 2017 06; 15(3):e429-e435.
    View in: PubMed
    Score: 0.003
  64. Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters. Clin Cancer Res. 2017 04 01; 23(7):1722-1732.
    View in: PubMed
    Score: 0.003
  65. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer. 2016 09 06; 16:721.
    View in: PubMed
    Score: 0.003
  66. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer. 2017 04; 15(2):e205-e208.
    View in: PubMed
    Score: 0.003
  67. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 2016 Jul 19; 7(29):46321-46334.
    View in: PubMed
    Score: 0.003
  68. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun. 2016 05 31; 7:11674.
    View in: PubMed
    Score: 0.003
  69. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
    View in: PubMed
    Score: 0.003
  70. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience. BJU Int. 2016 08; 118(2):264-71.
    View in: PubMed
    Score: 0.003
  71. Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. Clin Genitourin Cancer. 2016 Apr; 14(2):e187-93.
    View in: PubMed
    Score: 0.003
  72. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res. 2016 Mar 15; 22(6):1520-30.
    View in: PubMed
    Score: 0.003
  73. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res. 2015 Nov 15; 75(22):4949-59.
    View in: PubMed
    Score: 0.003
  74. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62.
    View in: PubMed
    Score: 0.003
  75. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21.
    View in: PubMed
    Score: 0.003
  76. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.003
  77. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun; 13(3):218-24.
    View in: PubMed
    Score: 0.002
  78. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9.
    View in: PubMed
    Score: 0.002
  79. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122.
    View in: PubMed
    Score: 0.002
  80. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76.
    View in: PubMed
    Score: 0.002
  81. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
    View in: PubMed
    Score: 0.002
  82. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res. 2014 Aug 15; 20(16):4218-27.
    View in: PubMed
    Score: 0.002
  83. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014 May 20; 7(326):ra47.
    View in: PubMed
    Score: 0.002
  84. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67(2):310-8.
    View in: PubMed
    Score: 0.002
  85. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma. 2014 Jul; 55(7):1625-34.
    View in: PubMed
    Score: 0.002
  86. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. 2014 Mar; 113(3):376-82.
    View in: PubMed
    Score: 0.002
  87. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014 Mar; 191(3):611-8.
    View in: PubMed
    Score: 0.002
  88. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30.
    View in: PubMed
    Score: 0.002
  89. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9.
    View in: PubMed
    Score: 0.002
  90. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
    View in: PubMed
    Score: 0.002
  91. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem. 2012 Jan; 4(1):107-19.
    View in: PubMed
    Score: 0.002
  92. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 2011 Dec; 20(12):1677-84.
    View in: PubMed
    Score: 0.002
  93. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25.
    View in: PubMed
    Score: 0.002
  94. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010 Jan 01; 116(1):57-65.
    View in: PubMed
    Score: 0.002
  95. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther. 2009 Nov; 8(22):2153-9.
    View in: PubMed
    Score: 0.002
  96. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010 Mar; 34(3):364-72.
    View in: PubMed
    Score: 0.002
  97. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81.
    View in: PubMed
    Score: 0.002
  98. Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther. 2003 Nov-Dec; 2(6):707-12.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.